7 results found.

Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage I Follicu Clinical Trial using cabozantinib-s-malate; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy.
cabozantinib-s-malate; laboratory biomarker analysis

Recurrent Thyroid Cancer Clinical Trial using lapatinib ditosylate; dabrafenib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer.
lapatinib ditosylate; dabrafenib; pharmacological study; laboratory biomarker analysis

Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyr Clinical Trial using dabrafenib; trametinib; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years or older.
- A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma.
dabrafenib; trametinib; Correlative Studies

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Pre Clinical Trial using sorafenib tosylate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 30 years.
- A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma.
sorafenib tosylate; pharmacological study; laboratory biomarker analysis

Recurrent Thyroid Cancer, Stage I Follicular Thyroid Cancer, Stag Clinical Trial using cediranib maleate; lenalidomide; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 18 years or older.
- Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer.
cediranib maleate; lenalidomide; laboratory biomarker analysis

Medullary Thyroid Cancer Clinical Trial using GI-6207

GlobeImmune - Recruiting 18 years or older.
- A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer.
GI-6207